The 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, took place on the 4–6 May. ESH AL focused on our increased understanding of acute leukemias and the revolutionary new therapies being developed.

Exciting topics from this year’s conference include expert insights into the utility and impact of MRD, problems posed by relapsed/refractory disease, and novel immuno-oncology approaches.

ESH AL 2018

04–06 May 2018 | Budapest, Hungary

ESH AL 2018

04–06 May 2018 | Budapest, Hungary

The 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, took place on the 4–6 May. ESH AL focused on our increased understanding of acute leukemias and the revolutionary new therapies being developed.

Exciting topics from this year’s conference include expert insights into the utility and impact of MRD, problems posed by relapsed/refractory disease, and novel immuno-oncology approaches.

An overview of 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias 1:14
An overview of 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias
Arnold Ganser • 4 May 2018
From bench to the bedside: understanding the genetic changes in AML 3:15
From bench to the bedside: understanding the genetic changes in AML
Arnold Ganser • 4 May 2018
Challenges with the identification of ALL subtypes 1:38
Challenges with the identification of ALL subtypes
Charles Mullighan • 4 May 2018
Current understandings of ALL approaches 2:24
Current understandings of ALL approaches
Charles Mullighan • 4 May 2018
The devastating effects of relapsed or refractory AML 3:00
The devastating effects of relapsed or refractory AML
Arnold Ganser • 4 May 2018
Overcoming the issues with clinical trial recruitment 1:37
Overcoming the issues with clinical trial recruitment
Arnold Ganser • 4 May 2018
Increasing the effectiveness of ALL therapies 2:18
Increasing the effectiveness of ALL therapies
Charles Mullighan • 4 May 2018
Midostaurin: the first drug to receive approval for AML since 2000 2:28
Midostaurin: the first drug to receive approval for AML since 2000
Arnold Ganser • 4 May 2018
Minimal residual disease: a key determinant of ALL treatment response 3:01
Minimal residual disease: a key determinant of ALL treatment response
Charles Mullighan • 4 May 2018
Improving response to ALL therapies 2:08
Improving response to ALL therapies
Charles Mullighan • 4 May 2018
Finding the right targets for CAR T-cell therapy in AML 1:41
Finding the right targets for CAR T-cell therapy in AML
Arnold Ganser • 4 May 2018
Combination therapy for the treatment of AML 1:17
Combination therapy for the treatment of AML
Christoph Röllig • 4 May 2018
The importance of MRD assessment in all phases of ALL treatment 0:46
The importance of MRD assessment in all phases of ALL treatment
Noelle Frey • 4 May 2018
Applying the right therapies to the right AML patient population 1:41
Applying the right therapies to the right AML patient population
Christoph Röllig • 4 May 2018
The CAR T-cell therapy race 1:05
The CAR T-cell therapy race
Noelle Frey • 4 May 2018
CAR T-cell therapy and ALL: the current landscape 1:58
CAR T-cell therapy and ALL: the current landscape
Noelle Frey • 4 May 2018
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals